Insights  /  Go-to-Market
Medtech · Hospital access

Hospital & tender access in Germany

German hospital procurement is committee-driven, slow and rule-bound. A reimbursement code doesn't get your product used — a hospital still has to choose it, through a process where clinicians, pharmacy, procurement and controlling all have a say. Winning it is a campaign, not a pitch.

9 min read By Alexander Baranov, Commercial & Partnerships Lead Updated 2026
In one paragraph

Germany has around 1,900 hospitals — public, non-profit and private chains — and buying is rarely a single decision. Access runs through three routes: tenders (public hospitals follow EU / German procurement law), group purchasing organisations (Einkaufsgemeinschaften) that aggregate demand across many hospitals, and direct or distributor relationships. In every case a committee decides — clinical champions, pharmacy, procurement and controlling — and the second meeting is earned by evidence, reliability and a credible local presence, not a cold pitch.

Access is a campaign, not a sale

A CE mark lets you sell and a reimbursement code lets you be paid — but neither makes a hospital use your product. That decision is made inside the hospital, by several people, over months.

For a foreign manufacturer used to a champion-led sale, the German hospital is a shock: no single buyer, a formal process, budget pressure, and value-analysis committees that weigh clinical benefit against cost. Access is won by understanding who sits at the table and giving each of them what they need — and by being reliably present long enough to be evaluated at all.

In a German hospital, nobody buys alone — so nobody is sold alone.

Who decides

The buying committee — nobody buys alone

A new product usually needs several people to say yes. Win the clinician but lose controlling and you don't get in. Each seat weighs something different.

Clinical champion

The treating physician

Wants the clinical benefit and the evidence. Necessary — but not sufficient on their own.

Hospital pharmacy

Krankenhausapotheke

Controls the formulary and supply; weighs safety, handling and stock.

Procurement

Einkauf

Runs the process, tenders and contracts; wants terms, reliability and price.

Controlling / finance

The budget owner

Weighs the total cost against the DRG or NUB payment — where a premium product is won or lost.

Hygiene / MedTech

Technical & safety

Assesses integration, hygiene, training and technical fit with existing systems.

Value analysis

New-product committee

Many hospitals run a formal committee that scores new products on benefit vs cost before adoption.

Map the table before the first meeting. Knowing who weighs what — and arming your champion to answer procurement and controlling — is the difference between a pilot and a polite no.

The three access routes

Product reaches a German hospital through one of three channels — and most manufacturers use more than one.

01 · Tenders

Public procurement

Public hospitals must tender above certain values under EU / German procurement law — a formal, criteria-driven process you qualify for and bid into.

02 · Group purchasing

Einkaufsgemeinschaften

Purchasing organisations aggregate demand across many hospitals and negotiate framework agreements — win one and you reach dozens of hospitals.

03 · Direct / distributor

Key accounts & specialists

Direct key-account relationships or specialist distributors — often the route for premium, technical or clinician-driven products.

The hospital landscape

Around 1,900 hospitals fall into three ownership types, and increasingly into large groups that centralise purchasing.

  • Public — run by municipalities, districts or states (e.g. Vivantes in Berlin), and the university hospitals (Uniklinika) that anchor research and complex care.
  • Non-profit / freigemeinnuetzig — often church-affiliated foundations, a large share of German hospitals.
  • Private chains — groups such as Helios (Fresenius), Asklepios and Sana operate many hospitals with centralised procurement.

The trend is consolidation: as chains and purchasing groups grow, buying decisions move up from the single hospital to the group — which changes who you need to convince.

Tenders & procurement law

Public hospitals are contracting authorities, so above EU thresholds their purchases follow public-procurement law: the GWB and the procurement ordinance (VgV), with lower-value contracts under the UVgO.

  • Where it's published. Above the EU threshold, tenders appear on TED and national portals; below, on national platforms.
  • What they assess. Not price alone — award criteria weigh quality, technical fit, service and lifecycle cost. Qualification (references, certifications) is a gate before the bid.
  • Why it matters early. Tender specifications can be shaped by clinical needs identified before publication — so being known to the hospital ahead of the tender is a real advantage.

Earning the second meeting

German hospitals commit gradually. Trust, reliability and evidence decide who gets past the first conversation.

Adoption typically starts small — a pilot or a single department — and broadens as the product proves itself. What earns that first step:

Clinical evidenceHealth-economic caseLocal contactabilityReliable supplyTraining & serviceA credible reference

A credible presence on the ground is often the precondition for being evaluated at all — the second meeting is earned by trust and evidence, not a cold pitch from abroad.

A code isn't a purchase

Even with reimbursement secured, the hospital still has to choose to buy and use your product — and if it's bundled into a DRG, the budget pressure works against a premium item. Reimbursement and hospital access are two linked but separate battles: one gets you paid if used, the other gets you used.

Getting the code is the reimbursement fight. Getting bought is the hospital fight. You need both. See medical device reimbursement.

Where companies go wrong

  • Selling only to the clinician. The champion opens the door; procurement and controlling decide whether you walk through it.
  • Ignoring the total-cost story. A premium product needs a health-economic case, not just clinical data.
  • Showing up only at tender time. By publication, the specification may already reflect a competitor's product.
  • No local presence. Without contactable local support, hospitals often won't start the evaluation at all.
AB
By Alexander Baranov
Commercial & Partnerships Lead · hospital & distributor access
Selling into German hospitals?

We map the table — and open the door.

In a focused session we identify the right access route (tender, purchasing group or direct), the decision-makers to convince, and the evidence and local setup that earn the second meeting — and we approach the accounts worth starting with.